Compare NXL & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | HKPD |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | Hong Kong |
| Employees | 7 | 27 |
| Industry | Medical Specialities | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 6.9M |
| IPO Year | N/A | N/A |
| Metric | NXL | HKPD |
|---|---|---|
| Price | $0.41 | $0.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 208.0K | 32.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.28 | N/A |
| Revenue Next Year | $185.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.58 |
| 52 Week High | $2.57 | $2.74 |
| Indicator | NXL | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 40.26 |
| Support Level | $0.37 | N/A |
| Resistance Level | $0.62 | $0.89 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 8.14 | 41.90 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.